ALung Technologies, Inc. (the “Company”) develops intra and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders

The Company’s current lead product under development is the Hemolung™. This device is an extracorporeal gas exchange device that circulates blood via a small catheter the same size as a dialysis catheter. By directly delivering oxygen (O2) to the blood and removing carbon dioxide (CO2) from the blood, the Hemolung is expected to deliver a clinically and economically superior ventilation solution than mechanical ventilation. This device is capable of supporting patients with acute breathing problems for 7 days, providing their lungs a bridge to recovery.